Orthocell Remplir Approved for US DoD, VA

Orthocell Limited has secured approval for its Remplir nerve repair device to be used across the United States===United States Department of Defense (DoD) and Veterans Affairs (VA) hospital networks. This approval provides Orthocell access to approximately 51 DoD military hospitals and 170 VA medical centers across the United States, representing a significant expansion of its U.S. market access. The company plans to leverage its existing U.S. distributor network to target military and VA surgeons. This expansion follows the recent clinical use of Remplir in 23 surgical procedures on injured soldiers in Ukraine, demonstrating its effectiveness in conflict environments and suitability for major traumatic injuries. Orthocell's Managing Director, Paul Anderson, highlighted this as a major step forward in the company's U.S. commercial strategy.